← All drugs
Drug · FAERS side-effect profile with label screen

Diclofenac Topical side effects: what 35,510 FDA adverse event reports show

Diclofenac Sodium Topical · 1,212 reaction terms · 510,645 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Nonsteroidal anti-inflammatory drug (nsaid)

FDA label, Indications wording of the closest related product

Label matched

Diclofenac Sodium Topical (Diclofenac Sodium)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

35,510 reports · 78% serious · 6,889 with death outcome · 74% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Diclofenac sodium topical gel is indicated for the topical treatment of actinic keratoses (AK). Diclofenac sodium topical gel is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the topical treatment of actinic keratoses (AK). ( 1 )

FDA label, Indications and Usage

What it is

Diclofenac sodium topical gel, 3%, intended for dermatologic use, contains the active ingredient, diclofenac sodium, in a clear, transparent, colorless to slightly yellow or orange gel base. Diclofenac sodium is a white or slightly yellowish hygroscopic crystalline powder.

FDA label, Description section

Boxed warning

RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled adverse reaction 1Labeled (related wording) 4Lab value / disease marker 7Not in label — unassessed 27
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,172 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Lupus vulgaris8401,458.4
1,285.4–1,654.6ROR 1,493.7 · calibrated p 3e-19 ✓
412.6 EB05 389.7 · IC025 +8.3
3/3 methods agree
Not in label — unassessedserious n=840 · ♀ 100% (drug 74%) · 96% cliniciannot reported in cached trials
Anti-cyclic citrullinated peptide antibody4661,404.3
1,187.8–1,660.3ROR 1,423.0 · calibrated p 6e-19 ✓
405.1 EB05 375.2 · IC025 +8.0
3/3 methods agree
Lab value / disease markerserious n=466 · ♀ 100% (drug 74%) · 96% cliniciannot reported in cached trials
Swollen joint count increased2,0421,145.3
1,063.6–1,233.3ROR 1,215.1 · calibrated p 3e-18 ✓
385.0 EB05 371.2 · IC025 +8.4
3/3 methods agree
Lab value / disease markerserious n=2,041 · ♀ 100% (drug 74%) · 95% cliniciannot reported in cached trials
Rheumatic fever2,7671,041.6
979.6–1,107.6ROR 1,129.6 · calibrated p 6e-18 ✓
372.9 EB05 361.4 · IC025 +8.4
3/3 methods agree
Not in label — unassessedserious n=2,767 · ♀ 100% (drug 74%) · 94% cliniciannot reported in cached trials
Deep vein thrombosis postoperative1,2381,031.6
940.7–1,131.2ROR 1,068.8 · calibrated p 1e-17 ✓
370.4 EB05 353.4 · IC025 +8.2
3/3 methods agree
Not in label — unassessedserious n=1,238 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials
Grip strength144985.3
753.8–1,288.0ROR 989.3 · calibrated p 9e-17 ✓
349.3 EB05 304.0 · IC025 +7.1
3/3 methods agree
Not in label — unassessedserious n=144 · ♀ 100% (drug 74%) · 100% cliniciannot reported in cached trials
C-reactive protein511772.0
676.6–880.8ROR 783.2 · calibrated p 5e-16 ✓
328.2 EB05 305.0 · IC025 +7.8
3/3 methods agree
Lab value / disease markerserious n=511 · ♀ 100% (drug 74%) · 96% cliniciannot reported in cached trials
Anti-cyclic citrullinated peptide antibody positive3,987765.8
731.3–801.9ROR 862.5 · calibrated p 1e-16 ✓
330.6 EB05 322.1 · IC025 +8.3
3/3 methods agree
Lab value / disease markerserious PRR 244.3 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials
Facet joint syndrome1,628638.1
595.2–684.0ROR 668.7 · calibrated p 3e-15 ✓
303.7 EB05 291.5 · IC025 +8.0
3/3 methods agree
Not in label — unassessedserious n=1,628 · ♀ 100% (drug 74%) · 95% cliniciannot reported in cached trials
Duodenal ulcer perforation3,741620.8
593.5–649.3ROR 693.7 · calibrated p 2e-15 ✓
300.3 EB05 292.3 · IC025 +8.1
3/3 methods agree
Labeled — boxed warning
synonym match
serious PRR 221.0 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials
Rheumatoid factor positive2,910607.7
577.6–639.5ROR 661.9 · calibrated p 3e-15 ✓
297.1 EB05 288.2 · IC025 +8.1
3/3 methods agree
Lab value / disease markerserious n=2,909 · ♀ 100% (drug 74%) · 94% cliniciannot reported in cached trials
Swollen joint count121576.8
448.7–741.6ROR 578.8 · calibrated p 3e-14 ✓
277.4 EB05 238.3 · IC025 +6.7
3/3 methods agree
Not in label — unassessedserious n=121 · ♀ 100% (drug 74%) · 100% cliniciannot reported in cached trials
Adjustment disorder with depressed mood942522.8
479.0–570.5ROR 537.0 · calibrated p 3e-14 ✓
274.3 EB05 259.9 · IC025 +7.8
3/3 methods agree
Not in label — unassessedserious n=942 · ♀ 100% (drug 74%) · 96% cliniciannot reported in cached trials
Pemphigus5,732509.9
492.9–527.5ROR 607.9 · calibrated p 7e-15 ✓
271.9 EB05 266.1 · IC025 +8.0
3/3 methods agree
Not in label — unassessedserious PRR 200.8 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials
Hypocholesterolaemia139490.0
391.1–613.8ROR 491.9 · calibrated p 1e-13 ✓
257.0 EB05 223.1 · IC025 +6.8
3/3 methods agree
Not in label — unassessedserious n=139 · ♀ 100% (drug 74%) · 100% cliniciannot reported in cached trials
Retinitis718449.0
407.6–494.7ROR 458.3 · calibrated p 2e-13 ✓
252.1 EB05 237.0 · IC025 +7.6
3/3 methods agree
Not in label — unassessedserious n=718 · ♀ 100% (drug 74%) · 96% cliniciannot reported in cached trials
Dislocation of vertebra944438.5
403.3–476.9ROR 450.5 · calibrated p 2e-13 ✓
249.2 EB05 236.1 · IC025 +7.7
3/3 methods agree
Not in label — unassessedserious n=944 · ♀ 100% (drug 74%) · 95% cliniciannot reported in cached trials
X-ray abnormal729410.5
373.5–451.0ROR 419.0 · calibrated p 4e-13 ✓
239.5 EB05 225.3 · IC025 +7.6
3/3 methods agree
Lab value / disease markerserious n=729 · ♀ 100% (drug 74%) · 96% cliniciannot reported in cached trials
Hand deformity5,238396.9
383.8–410.5ROR 465.4 · calibrated p 1e-13 ✓
236.1 EB05 230.8 · IC025 +7.8
3/3 methods agree
Not in label — unassessedserious PRR 189.0 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials
Helicobacter infection3,696337.7
324.7–351.2ROR 376.8 · calibrated p 1e-12 ✓
213.8 EB05 208.0 · IC025 +7.6
3/3 methods agree
Not in label — unassessedserious PRR 166.3 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials
Sleep disorder due to general medical condition, hypersomnia type34304.2
201.0–460.6ROR 304.5 · calibrated p 5e-11 ✓
180.0 EB05 134.7 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=34 · ♀ 100% (drug 74%) · 100% cliniciannot reported in cached trials
Muscle injury2,608276.1
263.9–289.0ROR 297.9 · calibrated p 1e-11 ✓
187.3 EB05 181.4 · IC025 +7.4
3/3 methods agree
Not in label — unassessedserious PRR 149.4 · ♀ 100% (drug 74%) · 95% cliniciannot reported in cached trials
Peripheral venous disease1,265274.8
257.3–293.6ROR 285.0 · calibrated p 2e-11 ✓
186.4 EB05 178.0 · IC025 +7.4
3/3 methods agree
Not in label — unassessedserious n=1,263 · ♀ 100% (drug 74%) · 94% cliniciannot reported in cached trials
Seronegative arthritis353271.9
239.8–308.4ROR 274.7 · calibrated p 3e-11 ✓
183.8 EB05 168.2 · IC025 +7.0
3/3 methods agree
Not in label — unassessedserious n=353 · 95% cliniciannot reported in cached trials
Folliculitis3,101254.2
244.1–264.9ROR 278.5 · calibrated p 2e-11 ✓
177.0 EB05 171.9 · IC025 +7.4
3/3 methods agree
Not in label — unassessedserious PRR 153.2 · ♀ 100% (drug 74%) · 95% cliniciannot reported in cached trials
Pericarditis4,482217.9
210.9–225.1ROR 249.2 · calibrated p 5e-11 ✓
158.7 EB05 154.8 · IC025 +7.2
3/3 methods agree
Not in label — unassessedserious PRR 117.8 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials
Synovitis4,593202.1
195.7–208.6ROR 232.0 · calibrated p 1e-10 ✓
150.1 EB05 146.5 · IC025 +7.2
3/3 methods agree
Not in label — unassessedserious PRR 115.6 · ♀ 99% (drug 74%) · 93% cliniciannot reported in cached trials
C-reactive protein abnormal1,600197.0
186.3–208.3ROR 206.2 · calibrated p 3e-10 ✓
147.1 EB05 141.2 · IC025 +7.1
3/3 methods agree
Lab value / disease markerserious n=1,600 · ♀ 100% (drug 74%) · 94% cliniciannot reported in cached trials
Porphyria acute320178.4
157.5–202.2ROR 180.1 · calibrated p 1e-9 ✓
135.7 EB05 123.7 · IC025 +6.6
3/3 methods agree
Not in label — unassessedserious n=320 · ♀ 100% (drug 74%) · 94% cliniciannot reported in cached trials
Inspiratory capacity decreased62171.7
129.4–227.9ROR 172.0 · calibrated p 3e-9 ✓
127.7 EB05 103.1 · IC025 +5.6
3/3 methods agree
Not in label — unassessedserious n=62 · ♀ 0% (drug 74%) · 100% cliniciannot reported in cached trials
Lymphatic fistula22166.2
103.5–266.9ROR 166.3 · calibrated p 1e-8 ✓
116.6 EB05 81.2 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=22 · 100% cliniciannot reported in cached trials
Breast cancer stage iii1,348156.7
147.7–166.3ROR 162.9 · calibrated p 2e-9 ✓
123.4 EB05 118.0 · IC025 +6.8
3/3 methods agree
Not in label — unassessedserious n=1,348 · ♀ 100% (drug 74%) · 94% cliniciannot reported in cached trials
Bone erosion689142.7
131.4–155.0ROR 145.5 · calibrated p 6e-9 ✓
114.4 EB05 107.4 · IC025 +6.6
3/3 methods agree
Not in label — unassessedserious n=688 · ♀ 100% (drug 74%) · 97% cliniciannot reported in cached trials
Lip dry1,679136.3
129.4–143.6ROR 143.0 · calibrated p 7e-9 ✓
110.5 EB05 106.1 · IC025 +6.7
3/3 methods agree
Not in label — unassessedserious n=1,675 · ♀ 100% (drug 74%) · 95% cliniciannot reported in cached trials
Wound5,149134.4
130.6–138.2ROR 157.0 · calibrated p 3e-9 ✓
109.3 EB05 106.8 · IC025 +6.7
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 106.2 · serious PRR 95.6 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials
Grip strength decreased1,559128.1
121.4–135.2ROR 134.0 · calibrated p 1e-8 ✓
105.1 EB05 100.8 · IC025 +6.6
3/3 methods agree
Not in label — unassessedserious n=1,553 · ♀ 99% (drug 74%) · 94% cliniciannot reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Liver injury6,82013.613.3–13.9signal
Interstitial lung disease1,5269.59.1–10.0signal
Hyperglycaemia / diabetes3,5226.15.9–6.3signal
Serious infection5,4044.24.1–4.3signal
Depression1,9404.13.9–4.3signal
Gi bleeding1,1433.73.5–3.9signal
Pancreatitis3772.82.5–3.1signal
Anaphylaxis / angioedema5782.72.5–3.0signal
Rhabdomyolysis / myopathy3282.42.1–2.7signal
Fall / fracture1,4032.22.1–2.3signal
Thrombocytopenia7732.11.9–2.2raised
Severe cutaneous reaction2331.91.6–2.1raised
Tendon disorder1171.81.5–2.2raised
Kidney injury1,3161.71.6–1.8raised
Hyponatraemia2241.61.4–1.9raised
Anaemia7881.61.4–1.7raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Diclofenac Topical as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)7,7063.5
3.4–3.5ROR 4.2 · calibrated p 0.350
3.5 EB05 3.4 · IC025 +1.8
3/3 methods agree
Reporting / coding artifactage-adj. PRR 3.5 · serious PRR 5.9not reported in cached trials
Pain7,4447.2
7.1–7.4ROR 8.9 · calibrated p 0.048 ✓
7.1 EB05 7.0 · IC025 +2.8
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 6.3 · serious PRR 8.0not reported in cached trials
Fatigue (tiredness)7,0255.4
5.3–5.5ROR 6.5 · calibrated p 0.123
5.3 EB05 5.2 · IC025 +2.4
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 4.4 · serious PRR 7.2 · ♀ 94% (drug 74%)not reported in cached trials
Rheumatoid arthritis6,41135.5
34.6–36.3ROR 43.0 · calibrated p 3e-5 ✓
33.5 EB05 32.8 · IC025 +5.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 27.0 · serious PRR 30.0 · ♀ 99% (drug 74%) · 91% cliniciannot reported in cached trials
Rash6,1288.5
8.3–8.6ROR 10.0 · calibrated p 0.032 ✓
8.3 EB05 8.2 · IC025 +3.0
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 7.4 · serious PRR 13.2 · ♀ 96% (drug 74%)NCT02121002: 1/391 (0.3%) on Diclofenac Topical
Abdominal discomfort6,03422.1
21.6–22.6ROR 26.4 · calibrated p 5e-4 ✓
21.3 EB05 20.9 · IC025 +4.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 17.7 · serious PRR 34.7 · ♀ 99% (drug 74%)not reported in cached trials
Systemic lupus erythematosus5,897118.2
115.2–121.3ROR 141.5 · calibrated p 7e-9 ✓
98.4 EB05 96.3 · IC025 +6.6
3/3 methods agree
Not in label — unassessedage-adj. PRR 102.3 · serious PRR 74.3 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials
Alopecia (hair loss)5,79417.9
17.5–18.3ROR 21.2 · calibrated p 0.002 ✓
17.4 EB05 17.0 · IC025 +4.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 14.2 · serious PRR 27.1 · ♀ 100% (drug 74%) · 91% cliniciannot reported in cached trials
Off label use (used outside approved label)5,7633.9
3.8–4.0ROR 4.5 · calibrated p 0.295
3.9 EB05 3.8 · IC025 +1.9
3/3 methods agree
Reporting / coding artifactage-adj. PRR 3.8 · serious PRR 4.9not reported in cached trials
Pemphigus5,732509.9
492.9–527.5ROR 607.9 · calibrated p 7e-15 ✓
271.9 EB05 266.1 · IC025 +8.0
3/3 methods agree
Not in label — unassessedserious PRR 200.8 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials
Swelling5,45036.6
35.6–37.5ROR 43.0 · calibrated p 3e-5 ✓
34.5 EB05 33.7 · IC025 +5.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 29.4 · serious PRR 40.8 · ♀ 98% (drug 74%) · 92% cliniciannot reported in cached trials
Arthropathy5,26161.5
59.9–63.1ROR 72.0 · calibrated p 1e-6 ✓
55.7 EB05 54.4 · IC025 +5.7
3/3 methods agree
Not in label — unassessedage-adj. PRR 48.0 · serious PRR 49.8 · ♀ 99% (drug 74%) · 92% cliniciannot reported in cached trials
Joint swelling5,25326.9
26.2–27.6ROR 31.4 · calibrated p 2e-4 ✓
25.7 EB05 25.2 · IC025 +4.6
3/3 methods agree
Not in label — unassessedage-adj. PRR 22.3 · serious PRR 32.3 · ♀ 96% (drug 74%) · 91% cliniciannot reported in cached trials
Hand deformity5,238396.9
383.8–410.5ROR 465.4 · calibrated p 1e-13 ✓
236.1 EB05 230.8 · IC025 +7.8
3/3 methods agree
Not in label — unassessedserious PRR 189.0 · ♀ 100% (drug 74%) · 93% cliniciannot reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Methotrexate Sodium ↔ Rheumatoid Arthritis.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Diclofenac Topical?

In FDA FAERS, the most frequently co-reported reaction terms for Diclofenac Topical are pain, fatigue, rheumatoid arthritis, rash, abdominal discomfort, systemic lupus erythematosus. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Diclofenac Topical have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.

Do FAERS signals prove that Diclofenac Topical causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.